Maurocalcine, analogues thereof and their therapeutical uses

Details Maurocalcine, analogues thereof and their therapeutical uses Maurocalcine, analogues thereof and their therapeutical uses

2008-01-15

2008-01-15

Tsang, Cecilia J. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600

Reexamination Certificate

active

10220833

ABSTRACT:
Maurocalcine, a novel toxin isolated from the venom of the Tunisian chactidae scorpionScorpio maurus palmatus, has the amino acid sequence GDCLPHLKLCKENKDCCSKKCKRRGTNIEKRCR (SEQ. ID. No. 1). It potently and reversibly modifies channel gating behaviour of type 1 ryanodine receptor (RyR1) by inducing prominent subconductance behavior. Maurocalcine and its bioactive structural analogues—preferably those containing the KKCKRR motif corresponding to part of the II-III loop of the alpha1S subunit of the voltage-dependent skeletal muscle calcium channel dihydropyridine receptor—appear to possess a therapeutic potential, notably as candidate immuno-suppressive drugs, and for the treatment of pathologies in humans that may involve a dysfunction of calcium channels.

REFERENCES:
patent: 6162430 (2000-12-01), Hammock et al.
patent: 2002/0037275 (2002-03-01), Hammock et al.
Elements, Atoms, and Molecules, pp. 1-2, printed Jul. 27, 2005, http://www.nyu.edu/pages/mathmol/textbood/compounds.html.
Esteve, et al., Critical Amino Acid Residues Dtermne the Binding Affinity and the Ca2+ Release Efficacy of Maurocalcine in Skeletal Muscle Cells, The Journal of Biological Science, Sep. 26, 2003, vol. 278, No. 39, pp. 37822-37831.
On-line Medical Dictionary, Oct. 9, 1997, printed Jul. 27, 2005, p. 1, http://cancerweb.ncl.ac.uk/cgi.bin/omd?immunosuppressive+drug.
Lazarovici, et al., Insect Toxic Components from the Venom of a Chactoid Scorpion, Scorpio maurus palmuatus (Scorpionidae), The Journal of Biological Chemistry, Jul. 25, 1982, vol. 257, No. 14, pp. 8397-8404.
Riccardo Zucchi and Simonetta Ronca-Testoni, The Sarcoplasmic Reticulum Ca2+ Channel/Ryanodine Receptor: Modulation by Endogenous Effectors, Drugs and Disease States, Pharmacological Review, 1997, p. 1-51.
Dulhunty, et al., Agonists and antagonists of the cardiac ryanodine receptor: Potential therapeuctic agents?, Pharacology & Therapeutics, 2006 (Article in Press), pp. 1-17.
George, et al., Ryanodine receptor and ventricular arrhythmias: Emerging trends in mutation, mechanisms and therapies, Journal of Molecular and Cellular Cardiology, 2006 (Article In Press), pp. 1-17.
Rudinger, Peptide Hormones, (Jun. 1976) 1,5-6.
PubMed, www.pubmed.gov, 2006, pp. 1-42, http://www.ncbi.nih.gov/entrez/quiry.fcgi, printed Dec. 20, 2006.
El-Hayek, et al., Peptide Probe of Ryanodine Receptor Function, The Journal of Biological Chemistry, Dec. 1, 1995, vol. 270, No. 48,pp. 28696-28704.
Zamudio Fernando Z et al: “Primary Structure and Synthesis of Imperatoxin”, Febs Letters, 1997, pp. 385-389, vol. 405, No. 3.
Zamudio Fernando Z et al:“The Mechanism of Inhibition of Ryanodine Receptor Channels by Imperatoxin”, Journal of Biological Chemistry, 1997, pp. 11886-11894, vol. 272, No. 18.
Fajloun Z et al.: “Chemical Synthesis and Characterization of Maurocalcine”, Febs Letters, Mar. 10, 2000, pp. 179-185, vol. 469, No. 2-3.
Mosbah Amor et al.: “A New Fold in the Scorpian Toxin Family”, Proteins, Aug. 15, 2000, pp. 436-442, vol. 40, No. 3.

Affiliated with

Also associated with

Rating

Maurocalcine, analogues thereof and their therapeutical uses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Maurocalcine, analogues thereof and their therapeutical uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Maurocalcine, analogues thereof and their therapeutical uses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3927335